ServiceXS is an expert in genomic analysis, including next generation and whole genome sequencing. It is a research-intensive SME with extensive technical expertise and access to the state-of-the-art genomics technologies. ServiceXS prides itself on firsts: the first European company to provide next-generation sequencing services to its customers in 2006, the first company worldwide to offer single molecule sequencing technology in 2010, and the first European lab to obtain ion-proton equipment in 2012.

Within sysVASC, ServiceXS will contribute whole genome sequencing, miRNAomics, and relevant bioinformatics tools for advanced dynamic modelling and model based cluster analysis.



© biolution GmbH

Prof. Dr. Bart Janssen

Bart Janssen has worked with ServiceXS since 2007 and holds an honorary professorship with the Ruprecht-Karls University of Heidelberg. He is a molecular geneticist with a special interest in positional cloning and molecular diagnostics. From 1996 to 2007 he was the head of the molecular diagnostics laboratory at the Institute of Human Genetics in Heidelberg. He is now Innovation and Quality Manager at ServiceXS and network coordinator of the European project FAST-SEQ. He has over 60 peer reviewed publications and patents.

© ServiceXS



1 Barrett, J.H., et al. (2011) Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet. 43, 1108-13.

2 Peters, V., et al. (2010). Relevance of allosteric confirmations and homocamosine concentration on carnosinase (CNl) activity. Amino Acids. 38, 1607-15.

 3 Janssen, B., et al. (2005) Carnosine as a protective factor in diabetic nephropathy: Association with a leucine repeat of the camosinase gene CNDPl. Diabetes. 54, 2320-2327.

By continuing to use the site, you agree to the use of cookies. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.